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Available online xxxxBackground: Low back pain is a highly prevalent health problem around theworld, affecting 50% to 85% of people
at some point in life. The purpose of this systematic review is to summarize the previous proton magnetic reso-
nance spectroscopy studies on brain chemical changes in patients with chronic low back pain (CLBP).
Methods: We identiﬁed relevant studies from a literature search of PubMed and EMBASE from 1980 to March
2016. Data extraction was performed on the subjects' characteristics, MRS methods, spectral analyses, cerebral
metabolites and perceptual measurements.
Results: The review identiﬁed 9 studies that met the inclusion criteria, comprised of data on 135 CLBP subjects
and 137 healthy controls. Seven of these studies reported statistically different neurochemical alterations in pa-
tients with CLBP. The results showed that compared to controls, CLBP patients showed reductions of 1)N-acetyl-
aspartate (NAA) in the dorsolateral prefrontal cortex (DLPFC), right primary motor cortex, left somatosensory
cortex (SSC), left anterior insula and anterior cingulate cortex (ACC); 2) glutamate in the ACC; 3) myo-inositol
in the ACC and thalamus; 4) choline in the right SSC; and 5) glucose in the DLPFC.
Conclusion: This review provides evidence for alterations in the biochemical proﬁle of the brain in patients with
CLBP, which suggests that biochemical changes may play a signiﬁcant role in the development and pathophysi-
ology of CLBP and shed light on the development of new treatments for CLBP.
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##These 29 studies mainly focused on concentrations of metabolites in the spinal cord,
paraspinal muscles and intervertebral discs of LBP patients.1. Introduction
Lowback pain (LBP) is a highly prevalent health problem around the
world (Kamper et al., 2015), affecting 50% to 85% of people at some
point in life (Becker et al., 2010). According to the Global Burden of Dis-
ease Study in 2013, LBP ranked ﬁrst in the top ten causes of years lived
with disability (YLDs) (Vos et al., 2015). When LBP persists for N-
6 months (Koes et al., 2006; Van Tulder et al., 2003), it is classiﬁed as
chronic low back pain (CLBP), which leads to considerable health care
costs (Dagenais et al., 2008). Since the precise causes and origins of
CLBP are unknown to 90% of patients (Koes et al., 2006), therapeutic
methods targeting LBP symptoms are often nonspeciﬁc and ineffective.
Recently, neuroimaging techniques have been used to advance our
understanding of back pain mechanisms (Giesecke et al., 2004;
Kobayashi et al., 2009; Lloyd et al., 2008). In vivo magnetic resonance
spectroscopy (MRS) is a non-invasive brain imaging method that can
explore metabolic concentrations within certain brain regions. MRS de-
tects radiofrequency signals generated by the magnetic nuclear spins of
magnetically active nuclei such as protons, phosphorus, carbon and
ﬂuorine, which are excited by external magnetic ﬁelds (Glunde and
Bhujwalla, 2011; Glunde et al., 2011). Compared with other nuclei, pro-
ton nuclei (1H) are widely used in MRS studies because of their high
magnetic sensitivity and natural abundance in tissues (Bulik et al.,
2013; Soares and Law, 2009). Another beneﬁt of in vivo 1H MRS is
that it can be conducted in clinical MRI scanners without any additional
hardware (Malet-Martino and Holzgrabe, 2011).
Unlike traditional functional MRI, which obtains a spatial map of
brain activity, 1H MRS voxel placement generates a graphical spectrum
of speciﬁc regions of the brain (Harris and Clauw, 2012). The peaks on
the spectra represent various cerebral metabolites, including N-acetyl-
aspartate (NAA), choline (Cho), creatine (Cr), myo-inositol (mI), gluta-
mate (Glu), glutamine (Gln), gamma-aminobutyric acid (GABA) and
glucose (Glc). Concentration changes of these metabolites are associat-
ed with numerous neurological diseases (Aguila et al., 2015; Bustillo et
al., 2010; Vrenken et al., 2005), and can sometimes be detected prior to
the onset of symptoms (Godbolt et al., 2006).
Over the past two decades, a growing number of proton magnetic
resonance spectroscopy (1HMRS) studies have been applied to investi-
gate biochemical changes in individuals with CLBP. Although results
from these studies have shown that CLBP patients exhibit altered 1H
MRS signal changes in different brain regions, some of the results ob-
tained appear contradictory. Therefore, we performed this systematic
review of previous 1HMRS studies on CLBP to summarize the biochem-
ical changes in brain regions of interest and to explore potential reasons
for those inconsistent ﬁndings.
2. Material and methods
We conducted a systematic search of published studies in PubMed
and EMBASE from 1980 to March 2016. The Medical Subject Headings
were “magnetic resonance spectroscopy” and “back pain”. The search
strategy also included keywords such as “magnetic resonance spectros-
copy”, “MRS”, “spectroscopy” and “back pain” to identify relevant stud-
ies. No language restrictions were applied. The reference lists of the
selected articles were also reviewed to search for additional relevant
studies. The protocol for this review was registered on PROSPERO
(http://www.crd.york.ac.uk/PROSPERO; CRD42016045845).
Titles and abstracts of potentially relevant studies were examined to
determine whether they fulﬁlled the following inclusion criteria: (1)
Studies compared LBP patients with healthy controls, and (2) studiesemployed 1H MRS to measure metabolite concentrations in the brain.
We excluded studies that (1) did not present original data, and (2) did
not recruit LBP patients. After reviewing the full texts, one studywas ex-
cluded because half of the patients in the study did not presentwith low
back pain symptoms.
Data extraction was performed for subject and control numbers,
gender, age, diagnostic tools, duration of LBP symptoms, comorbidities
with LBP, medications, clinical measurements, metabolites studied,
brain regions of interest, voxels of interest,MR scanner devices,magnet-
ic ﬁeld strengths, MRS sequences, repetition times, echo times, spectral
analysis software, metabolite quantiﬁcation methods (absolute quanti-
ﬁcation or ratios to Cr), and data inclusion criteria.
3. Results
Our literature search yielded 271 potentially relevant studies on pa-
tients with CLBP and healthy controls. 262 studies were excluded for
reasons listed in Fig. 1. Tables 1 and 2 and Fig. 2 summarize the charac-
teristics of the 9 included studies.
3.1. Subjects
The 9 studies recruited a total of 135 CLBP subjects and 137 healthy
controls. All of the studies except for one study (Siddall et al., 2006) re-
ported subject numbers by sex, which showed that themajority of sub-
jects were females. For diagnosis of CLBP, three of the included studies
adopted the diagnostic criteria of Merskey and Bogduk (Grachev et al.,
2000, 2002, 2003), and two studies utilized classiﬁcation from the Inter-
national Association for the Study of Pain (Grachev et al., 2002; Siddall
et al., 2006). All of the patients presented with LBP for N6 months.
Table 1
Patient characteristics.
Study Patients
(M)
Age mean
± SD
Duration of illness
(yrs)
Comorbidity (N) Stop
medication
VAS score Other clinical
measurement
Grachev et al.
(2000)
9 (7) 45 ± 6 9 ± 5 NM ≥24 h 61.81 ± 17.18 (of
100)
SF-MPQ, STAI
Grachev et al.
(2002)
12 (9) 47.5 ± 5.6 8.86 ± 4.4 Anxiety ≥24 h 61.81 ± 17.18 (of
100)
SF-MPQ, STAI
Grachev et al.
(2003)
10 (5) 49 ± 11 12.6 ± 6 Depression ≥24 h 64.6 ± 14.4 (of
100)
BDI, SF-MPQ
Gussew et al.
(2011)
10 (2) 22–52 1–5 NM ≥24 h 4.1 ± 1.1 LSSI
Gussew et al.
(2015)
13 (1) 54 ± 8 NM NM NM NM NM
Janetzki et al.
(2016)
19 (3) 55.3 13.3 ± 12.1 NM NM 6.3 ± 1.3 HADS-D, HADS-A
Sharma et al.
(2011)
11 (0) 33.6 ± 10.6 10.6 ± 8.3 Radiating leg pain (7) NM 5.9 ± 1.4 PE, SF-MPQ, FABQ, MODS,
BDI
Sharma et al.
(2012)
19 (4) 46.1 ± 11.3 8.8 ± 7.2 Radiating pain in buttocks (9) and/or
left leg (4)
NM 4.5 ± 1.9 SF-MPQ, FABQ, MODS, BDI
Siddall et al.
(2006)
32 (NM) NM ≥0.5 NM No NM SF-MPQ, DASS, RMDQ,
PSEQ, LSSI
Abbreviation: BDI, Beck Depression Inventory; DASS, Depression Anxiety Stress Scales; FABQ, Fear-Avoidance Belief Questionnaire; HADS-A, Hospital Anxiety and Depression Scale - Anx-
iety subscale; HADS-D, Hospital Anxiety andDepression Scale - Depression subscale; LSSI, lumbosacral spine imaging;M,male;MODS,ModiﬁedOswestryDisability Scale;N, number;NM,
not mentioned; PE, Physical examination; PSEQ, Pain Self-Efﬁcacy Questionnaire; RMDQ, Roland &Morris Disability Questionnaire; SF-MPQ, Short FormMcGill Pain Questionnaire; STAI,
State–Trait Anxiety Inventory; VAS, visual analog scale.
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was associated with anxiety (Grachev et al., 2002), another focused on
depression (Grachev et al., 2003), one study reported seven patients
with radiating leg pain, and another study (Sharma et al., 2012) report-
ed subjects with radiating pain in the buttocks and left leg. About 30% of
all patients refrained frommedication for at least 24 h before the study.
3.2. MRS method
Two studies collected data usingmulti-voxelMR spectroscopy imag-
ing (Sharma et al., 2012, 2011), whereas seven used single voxel spec-
troscopy (SVS) locations to analyze individual data (Grachev et al.,
2000, 2002, 2003; Gussew et al., 2015, 2011; Janetzki et al., 2016;
Siddall et al., 2006). Five studieswere performed using a 3.0 TMRI scan-
ner (Gussew et al., 2015, 2011; Janetzki et al., 2016; Sharma et al., 2012,Table 2
Summary of methods and results.
Study Metabolites ROI VOI Field
strength
Grachev et al.
(2000)
NAA, Cho, GABA, Glu, Gln,
Glc, Lac
DLPFC, Th, cingulate, Ins,
SMC, OFC, VC
SVS 1.5 T
Grachev et al.
(2002)
NAA, Cho, GABA, Glu, Gln,
Glc, mI, Lac
DLPFC, OFC, Th, cingulate SVS 1.5 T
Grachev et al.
(2003)
NAA DLPFC, ACC, OFC, Th SVS 1.5 T
Gussew et al.
(2011)
NAA, Cr, Cho, mI, Glu, Gln aI (L), ACC, Th (L) SVS 3 T
Gussew et al.
(2015)
Glx, GABA ACC, Ins (L), PC SVS 3 T
Janetzki et al.
(2016)
Glu, GABA ACC, Ins SVS 3 T
Sharma et al.
(2011)
NAA, Cho, mI, Glx SSC MVS 3 T
Sharma et al.
(2012)
NAA, mI M1 MVS 3 T
Siddall et al.
(2006)
Cho, Cr, Glx, mI, NAA ACC (L), PFC (L), Th (L) SVS 1.5 T
Abbreviation: ACC, anterior cingulate cortex; aI, anterior insula; Cho, choline; Cr, creatine; DLPF
tamine; Glu, glutamate; Glx, glutamate and glutamine; Ins, insula; Lac, lactate; MEGA-PRESS,
voxel spectroscopy; NAA, N-acetyl-aspartate; NSSD, non-statistically signiﬁcant difference; OFC
spectroscopy; ROI, region of interest; SMC, sensorimotor cortex; SSC, somatosensory cortex; S
Th, thalamus; TR, repetition time; VC, visual cortex.2011), and four studies utilized a 1.5 T scanner (Grachev et al., 2000,
2002, 2003; Siddall et al., 2006). Four studies used stimulated echo ac-
quisition mode sequences (STEAM) (Grachev et al., 2000, 2002, 2003;
Siddall et al., 2006), ﬁve studies used point resolved spectroscopy se-
quences (PRESS) (Gussew et al., 2015, 2011; Janetzki et al., 2016;
Sharma et al., 2012, 2011) and two also used MEscher-GArwood Point
RESolved Spectroscopy (MEGA-PRESS) (Gussew et al., 2015; Janetzki
et al., 2016). Repetition times ranged from 500 to 2500 ms. Echo times
ranged from 12 to 68 ms.
3.3. Spectral analysis
Metabolite concentrations were calculated using LCModel in four
studies (Gussew et al., 2015, 2011; Sharma et al., 2012, 2011), jMRUI
package in one study (Gussew et al., 2015), and Scion Image analysisMRS sequence TR (ms) TE
(ms)
Results
STEAM 500 12 NAA and Glc↓ in DLPFC
STEAM 1500 30 NAA↑ in OFC between high anxiety
groups
STEAM 1500 30 NAA↓ in the right DLPFC of CLBP
patients with depression
PRESS 2500 30 1. Glu↓↓ in the ACC
2. NAA↓ in left aI and ACC
3. mI↓ in ACC and left Th
PRESS/MEGA-PRESS 1800/1800 30/68 NSSD
PRESS/MEGA-PRESS 1800/2000 30/68 NSSD
PRESS 1500 30 1. NAA↓↓ in the left SSC
2. Cho↓ in right SSC
PRESS 1500 30 NAA↓ in right M1
STEAM 1500 25 MRS detected neurochemical changes
with high accuracy.
C, dorsolateral prefrontal cortex; GABA, gamma-aminobutyric acid; Glc, glucose; Gln, glu-
MEscher-GArwood Point RESolved Spectroscopy; mI, myo-inositol; MVS, multiple single
, orbital frontal cortex; PC, posterior cortex; PFC, prefrontal cortex; PRESS, point resolved
TEAM, stimulated echo acquisition mode; SVS, single voxel spectroscopy; TE, echo time;
Fig. 2. Biochemical changes in brain regions of CLBP patients.
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Classiﬁcation Strategy was speciﬁed in one study (Siddall et al., 2006).
Data inclusion criteria of two of the studies were (1) total brain
volume N 75%, (2) a SNR N 10, and (3) Cramer-Rao bounds for each neu-
rochemical b20% (Sharma et al., 2012, 2011). In one study, statistical
analysis was only conducted for data that exhibited (1)
FWHMNAA b 10 Hz, and (2) CRLBGln b 30% for Gln and Glx concentra-
tions (Gussew et al., 2011).
3.4. Cerebral metabolites
Cerebral metabolites were reported as a ratio to Cr in ﬁve studies
(Grachev et al., 2000, 2002, 2003; Gussew et al., 2015; Janetzki et al.,
2016) and absolute concentrations in three studies (Gussew et al.,
2011; Sharma et al., 2012, 2011). Three studies determined the absolute
concentrations; two studies utilized LCModel to calculate the metabo-
lite concentrations and corrected the LCModel output for the estimated
brain tissue fraction (Sharma et al., 2012, 2011), while the other study
used thewater signal referencemethod thatmultiplied the ratio ofmet-
abolic intensities to water signal intensities (assessed by LCModel) with
thewater concentration in brain tissue and corrected for factors such as
relaxation (Gussew et al., 2011).
3.4.1. NAA
Studies reported reductions of NAA in ﬁve brain regions, including
the dorsolateral prefrontal cortex (DLPFC), right primary motor cortex
(M1), left somatosensory cortex (SSC), left anterior insula (aI) and ante-
rior cingulate cortex (ACC) (Grachev et al., 2000; Gussew et al., 2011;
Sharma et al., 2012, 2011). There were no signiﬁcant differences in con-
centrations between patients and controls in the left M1, right SSC, thal-
amus, cingulate, insula, sensorimotor cortex (SMC), orbital frontal
cortex (OFC), and visual cortex (VC) (Grachev et al., 2000; Sharma et
al., 2012, 2011).
3.4.2. Glu, Gln, Glx and GABA
One study observed a signiﬁcant decrease in Glu in patients' ACC
(Gussew et al., 2011). There were no signiﬁcant changes of Glu/GABA
ratios in the ACC and insula (Janetzki et al., 2016). In the SSC, Glx con-
centrations were not signiﬁcantly changed (Sharma et al., 2011). Addi-
tionally, patients did not show any comparable Glx and GABA
interrelations in the ACC, left insula, and posterior cortex (Gussew et
al., 2015).
3.4.3. mI
Four studies investigated alterations ofmI; it was reduced in the ACC
and thalamus (Gussew et al., 2011), whereas in the DLPFC, OFC, cingu-
late and M1, concentrations of mI were not signiﬁcantly different be-
tween CLBP and control groups (Grachev et al., 2002; Sharma et al.,
2012). In one study targeted at the SSC, the authors found signiﬁcant
correlations between mI in the left and right SSC of CLBP patients
when compared to healthy controls (Sharma et al., 2011).3.4.4. Cho
Three studies investigated Cho changes in CLBP patients; there were
no signiﬁcant changes in the regions of DLPFC, thalamus, cingulate,
insula, SMC, OFC, VC, left aI, left thalamus and ACC (Grachev et al.,
2000; Gussew et al., 2011). Decreased Cho was observed in the right
SSC in CLBP patients as compared to controls in one study (Sharma et
al., 2011).
3.4.5. Glc
One study investigated the Glc changes in CLBP patients, and report-
ed reductions of Glc in the DLPFC (Grachev et al., 2000).
3.4.6. Cr
One study investigated the Cr changes in CLBP patients, and reported
no signiﬁcant changes in Cr between groups in the left aI, left thalamus
and ACC (Gussew et al., 2011).
Studies demonstrated neurochemical alterations in six brain regions
of CLBP patients compared to healthy controls: 1) decreased N-acetyl-
aspartate (NAA) and glucose (Glc) in the dorsolateral prefrontal cortex
(DLPFC); 2) signiﬁcantly decreased Glu and reduced NAA andmyo-ino-
sitol (mI) in the anterior cingulate cortex (ACC); 3) reduced NAA in the
left anterior insula (aI); 4) decreasedMI in the thalamus (Th); 5) signif-
icantly decreased NAA in the left somatosensory cortex (SSC) and de-
creased choline (Cho) in the right SSC; and 6) decreased NAA in the
right primary motor cortex (M1).
3.5. Association between the clinical measurements and the cerebral
metabolites
3.5.1. Pain
Several studies utilized the visual analog scale (VAS) to rate patients'
pain intensity, and six studies also measured pain using the Short Form
McGill Pain Questionnaire (SF-MPQ) (Grachev et al., 2000, 2002, 2003;
Sharma et al., 2012, 2011; Siddall et al., 2006). NAA levels in SSC were
found to be negatively correlated with pain duration (Sharma et al.,
2011). Reductions of NAA in the right DLPFCwere negatively associated
with pain behavior (as measured by total SF-MPQ scores) (Grachev et
al., 2003). In addition, studies also showed that pain intensity was pos-
itively correlated with Glu levels in the insula and Glx levels in the right
SSC, while pain intensity was negatively correlated with GABA concen-
trations in the insula (Janetzki et al., 2016; Sharma et al., 2011). No sig-
niﬁcant correlations were detected between neurochemicals (NAA, mI)
and pain characteristics (VAS and SF-MPQ) in the M1 (Sharma et al.,
2012).
3.5.2. Anxiety
In addition to CLBP related measurements, two studies used the
State–Trait Anxiety Inventory (STAI) to measure anxiety states
(Grachev et al., 2000, 2002). One study found signiﬁcant increases of
NAA in the OFC of high anxiety controls compared to high anxiety
37X. Zhao et al. / NeuroImage: Clinical 13 (2017) 33–38CLBP patients, and of low anxiety CLBP patients compared to high anx-
iety CLBP patients (Grachev et al., 2002). Another study using the Hos-
pital Anxiety and Depression Scale (HADS) reported anxiety as a
causal variable for reduced Glu in the ACC (Janetzki et al., 2016).
3.5.3. Depression
Participants in three studies (Grachev et al., 2003; Sharma et al.,
2012, 2011) completed theBeckDepression Inventory (BDI). NAA levels
in the right DLPFC were negatively correlated with depressive symp-
toms as measured by BDI scores (Grachev et al., 2003). One study
used the Hospital Anxiety and Depression Scale (HADS) (Janetzki et
al., 2016), and found depression and age could predict reduced GABA
in the ACC.
4. Discussion
In this study, we reviewed the previous 1H MRS studies on CLBP to
summarize the biochemical changes in CLBP patients. Seven of the
nine studies reviewed in this paper reported statistical differences in
brain metabolites in the thalamus, insula, SSC, ACC, DLPFC and M1 be-
tween healthy controls and patients, indicating brain chemical changes
in brain regions associated with pain processing (Apkarian et al., 2005;
Mouraux et al., 2011; Schmidt-Wilcke, 2015).
Additionally,we found reduction ofNAA inﬁve brain regions of CLPB
patients, and studies focused speciﬁcally on comorbid anxiety and de-
pression (Grachev et al., 2002, 2003) found exaggerated effects (Wand
et al., 2011). NAA is the acetylated form of the amino acid aspartate,
and is present in very high concentrations in brain neurons (Stagg and
Rothman, 2013). It has been recognized as a neuronal marker (Baslow
et al., 2007; Govindaraju et al., 2000), but its function remains contro-
versial. One hypothesis proposed for the role of NAA in the nervous sys-
tem is that NAA serves as an immediate precursor for the
neurotransmitter N-acetylaspartylglutamate, and NAA is reportedly re-
duced in neurodegenerative diseases (Moffett et al., 2007), which we
ascribe to neuronal loss and degeneration. In addition, several studies
suggesting that signiﬁcant brain atrophy exists in the right thalamus
(Apkarian et al., 2004), SSC (Schmidt-Wilcke et al.) and DLPFC
(Apkarian et al., 2004; Schmidt-Wilcke et al., 2006) of CLBP patients
seem to provide fairly compelling evidence to this assumption. Howev-
er, another documented function of NAA is that it is involved in brain
glucose consumption (O'Neill et al., 2000), which is also decreased in
the DLPFC of CLBP patients. We thus believe that reduced NAA in low
back pain patients may indicate that energy metabolism is altered as
well.
We also found a reduction of mI in CLBP patients. MI is primarily
present in glial cells (Chang et al., 2013) and has been proposed as a
marker for the density of glial cells (Govindaraju et al., 2000). Studies
on the biosynthesis of mI reported that it's generated in the
phosphoinositide (PI) second messenger system from a key molecule
in cellular signal transduction phosphatidylinositol 4,5-bisphosphate
(PIP2) (Coupland et al., 2005). Thus, a decrease in mI may suggest a
loss of glial cells or an alteration in glial metabolism caused by LBP.
The lower Cho concentration in the SSC of patients with LBP was an
unexpected ﬁnding because Cho levels are elevated in most neurologi-
cal diseases, including neoplasms, demyelination and gliosis (Glunde
et al., 2006; Inglese et al., 2003). Cho is a precursor of acetylcholine
(Ach) (Sarter and Parikh, 2005), which is a component of cell mem-
branes. Therefore, we think the low concentration of Cho in the SSC
can be explained by an increased uptake of Cho for the building of cell
membranes (Gustafsson et al., 2007) and for maintaining cell mem-
brane integrity.
Results from our study showed evidence of decreasedGlu in the ACC
of patients with CLBP, which is the most abundant excitatory neuro-
transmitter in the brain (Yang et al., 2011). In contrast to the results of
Gussew and colleagues (Gussew et al., 2011), Grachev and colleagues
(Grachev et al., 2000) reported no changes in Glu in the cingulate ofCLBP patients. This contradictory ﬁnding could be attributed to the
methodological differences between the two studies. Gussew and col-
leagues investigated absolute neurochemical concentrations of Glu
while Grachev and colleagues focused on Glu ratios to creatine. In addi-
tion, patients in the studies differed in pain intensities and duration of
pain symptoms, which may also inﬂuence the results.
The Cr ratio method was utilized for spectral quantiﬁcation in the
ﬁve studies. The Cr peak is relatively stable, and therefore is commonly
used as a concentration reference for comparison. One study indicated
no signiﬁcant differences in Cr resonance in the left aI, left thalamus
and ACC. However, this approach should be used with caution because
some studies reported alterations of this metabolite in several diseases
(Govindaraju et al., 2000). Thus, further investigations on Cr concentra-
tion in CLBP patients in different brain regions are needed.
No signiﬁcant differenceswere found in excitatory neurotransmitter
GABA levels in CLBP patients compared with healthy controls, despite
the role of GABA receptors in the modulation of pain perception
(Goudet et al., 2009). This lack of signiﬁcant ﬁndings may be due to ex-
tremely low concentrations of GABA in the brain and spectral resonance
overlaps with peaks of othermetabolites, which cannot be resolved un-
less spectral editing sequences like MEGA-PRESS (Mullins et al., 2014)
are utilized.
There are several limitations in our study. First, there are relatively
few subjects in each cohort, and confounding factors, such as anxiety
and depression, made it difﬁcult to identify speciﬁc biochemical
markers of CLBP. Secondly, in eight studies, almost half of the patients
had received prior treatment for CLBP. Although some of the patients
refrained from medications for at least 24 h before the study, it's not
clear whether this eliminates the inﬂuence caused by long-term medi-
cation use. Finally, although these MRS studies have detected neuro-
chemical alterations in these brain regions, the underlying causes of
thesemetabolic changes are not fully understood. Therefore, further in-
vestigation is needed to explore the pathophysiological relationship be-
tween the neurochemical alterations and CLBP.5. Conclusion
In summary, our study provides evidence for alterations in the bio-
chemical proﬁle of the brain in patients with CLBP, which suggest that
biochemical changes may play a signiﬁcant role in the manifestation
of CLBP. Future studies need to emphasize therapeutic response and
the relationships between brain metabolites and functions.Acknowledgements
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